

# An Overview of Adaptive Designs

Niranjan Dey

## Contents

<b>1</b>	<b>Introduction</b>	<b>2</b>
<b>2</b>	<b>Goals of Response Adaptive Designs</b>	<b>2</b>
<b>3</b>	<b>Different Families of Response Adaptive Designs</b>	<b>2</b>
<b>4</b>	<b>Urn Models</b>	<b>3</b>
4.1	Play-the-winner Rule . . . . .	3
4.2	Randomized play-the-winner Rule . . . . .	4
4.3	Drop-The-Loser Rule . . . . .	5
4.4	Advantages of Designs Based on Urn Models . . . . .	7
4.5	Some Drawbacks of Designs Based on Urn Models . . . . .	7
<b>5</b>	<b>Neyman Optimal Allocations</b>	<b>7</b>
<b>6</b>	<b>Target-Based Response-Adaptive Designs</b>	<b>8</b>
6.1	Sequential Maximum Likelihood Procedure . . . . .	8
6.2	Doubly Adaptive Biased Coin Design . . . . .	9
6.2.1	Role of Parameter $\gamma$ in Determining Variability of The Procedure . . . . .	10
<b>7</b>	<b>Important Issues in Adaptive Design</b>	<b>10</b>
7.1	Variability and Power of Using Adaptive Designs . . . . .	10
7.2	Sample Size of Adaptive Designs . . . . .	13
<b>8</b>	<b>Applying Adaptive Designs</b>	<b>13</b>
<b>9</b>	<b>Some Important Issues Regarding Adaptive Designs</b>	<b>14</b>

# 1 Introduction

- \* Response-adaptive designs, or response-adaptive randomization procedures, are designs that **change allocation away** from 50/50 based on responses observed so far in the trial.
  - The desired allocation proportion is usually motivated by an **ethical consideration of assigning more patients to better treatments**.
  - In this presentation, we discuss several classes of response-adaptive designs and the advantages and disadvantages of these designs, and the analysis of clinical trials based on adaptive designs.

## 2 Goals of Response Adaptive Designs

The two main goals of response-adaptive designs are :-

1. To maximize the individual patient's personal experience in a trial under certain restrictions.
  - (a) To reduce the overall number of patients (sample size) of a randomized clinical trial.

## 3 Different Families of Response Adaptive Designs

- \* The early ideas of adaptive designs can be traced back to Thompson and Robbins. Since then, two main families of response-adaptive designs have been proposed :-
  - **Design-driven**, where designs are driven by intuition and are **not optimal** in a formal sense.
  - Few examples of these type of designs are (**Urn Models**) :-
    1. Play-the-winner rule.
    2. Randomized play-the-winner rule.
    3. Drop-the-loser rule.
- \* **Target-based**, which is based on an optimal allocation target, where a **specific criterion** is **optimized** based on a **population model**.
  - Different examples of Target Based Adaptive Designs are :-
    1. Sequential maximum likelihood procedure.
    2. Doubly adaptive biased coin design.
- \* Let  $p_A$  be the probability of a success on treatment  $A$  and let  $p_B$  be the success probability of treatment  $B$ , with  $q_A = 1 - p_A$  and  $q_B = 1 - p_B$ .
  - In addition, let  $n$  be the total number of patients in a trial, let  $n_A$  be the number of patients assigned to treatment  $A$ , and let  $n_B$  be the number of patients assigned to  $B$ , so that  $n_A + n_B = n$ .
  - We here assume that the outcome can be observed relatively quickly.
  - Here we consider the simplest situation where two independent treatments “A” and “B” with binary outcomes (Success or failure) are compared in the course of a trial.

## 4 Urn Models

- \* One large class of response-adaptive designs is based on urn models which are specifically design driven, are based on Urn Models.
  - Following the ethical imperative, the Urn Models basically change the allocation in the course of a trial so that **more patients receive the treatment performing better** thus far in the trial.

### 4.1 Play-the-winner Rule

- \* This is one of the first response-adaptive designs, proposed by Zelen.
  - The first patient is equally likely to receive one of the two treatments.
  - The subsequent patient is assigned to the **same** treatment following a **successful** outcome, and to the **opposite** treatment following a **failure**.

Treatments	Assigned Treatment	Success/Failure
A B	A	S
A	A	F
B	B	F
A	A	S
A	A	F
B	B	S

- \* On average, the proportion of patients  $\frac{n_A}{n}$  assigned to treatment A is  $\frac{q_B}{q_A + q_B}$ .

- We simulate using R,  $10^3$  samples following Play-The-Winner Procedure where we consider  $p_A = 0.3$  and  $p_B = 0.6$ .
- Since, here we have taken  $p_A = 0.3, p_B = 0.6$ , the simulated allocation proportion for treatment A must converge to  $\frac{q_B}{q_A + q_B} = \frac{0.4}{1.1} = \frac{4}{11} \approx 0.364$ .
- We try to validate the above statements using simulation and plot the allocation proportions for both Treatment A & B as a function of increasing sample size  $n$ .





Figure 1: Plot of  $n_A/n$  and  $n_B/n$  as a function of  $n$

## 4.2 Randomized play-the-winner Rule

\* This rule was suggested by Wei and Durham and Wei.

- In this rule, the procedure is generally started with an urn containing one ball of each type corresponding to the two treatments.
- When a patient arrives, a ball is drawn from the urn and then replaced.
- The patient receives corresponding treatment.
- If the outcome is a **success**, **one ball of that type** is **added** to the urn.
- Otherwise, **one ball** of the **opposite type** is added to the urn.



✱ This design has the **same limiting allocation proportion** as the play-the-winner rule i.e  $\frac{n_A}{n} \xrightarrow{P} \frac{q_B}{q_A + q_B}$ .

- We simulate for the parameter values  $p_A = 0.2, p_B = 0.4$ .
- So from theoretical perspective, the observed allocation proportion for Treatment A must get closer to  $\frac{q_B}{q_A + q_B} = \frac{0.6}{1.4} \approx 0.429$  and for Treatment B, closer to  $\frac{q_A}{q_A + q_B} \approx 0.571$ .

### 4.3 Drop-The-Loser Rule

- ✱ According to this rule, the urn starts with **one ball of each treatment type** and **one ball of the so-called immigration type**.
  - When a patient arrives to be randomized to a treatment, a ball is taken from the urn.
  - If it is an immigration ball, the ball is replaced and two additional balls (one of each treatment type) are added to the urn.
  - If it is an actual treatment ball, a patient is assigned to corresponding treatment and response is observed.




Figure 2:  $n_A/n$  and  $n_B/n$  as a function of  $n$



❖ If response is a **failure**, the **ball** is **not returned** to the urn.

➡ If response is a **success**, the ball is **returned** to the urn (hence the urn composition remains unchanged).

➡ In this case also, the **limiting allocation proportion** is equal to  $\frac{q_B}{q_A + q_B}$ .

## 4.4 Advantages of Designs Based on Urn Models

1. We can stop the trial early or come to conclusions early.
  - (a) Because of early decision and greater flexibility it can reduce the potential cost.
  - (b) Urn models are intuitive and easy to implement in clinical trials.
  - (c) They shift the allocation probability to better treatments.

## 4.5 Some Drawbacks of Designs Based on Urn Models

1. In most of the models, we can see that it can only target a specific allocation proportion. This allocation is usually not optimal in a formal sense.
  - (a) It can only be applied to the clinical trials with binary or multinomial responses only. Modifications are necessary to apply urn models to clinical trials with continuous responses or survival responses.

## 5 Neyman Optimal Allocations

- \* Response-adaptive designs were introduced following the ethical goal to maximize an individual patient's personal experience in the trial.
  - Another **important goal** is to **maximize the power** of treatment comparison.
  - These two goals **usually compete** with each other.
  - Optimal allocation proportions are usually determined through some multiple-objective optimality criteria.
  - Consider the situation when two binomials are compared and the measure of interest is  $p_A - p_B$ .
- \* Let  $\hat{p}_A$  and  $\hat{p}_B$  be the corresponding maximum likelihood estimators of  $p_A$  and  $p_B$ . The allocation that minimizes the variance of  $\hat{p}_A - \hat{p}_B$  is the **Neymann Allocation** with :-

$$\frac{n_A}{n} = \frac{\sqrt{p_A q_A}}{\sqrt{p_A q_A} + \sqrt{p_B q_B}}$$

- An interesting fact about the **Neymann Allocation** scheme is that for some values of  $p_A$  and  $p_B$  it will assign more patients to the inferior treatment. Since, then

$$\begin{aligned} p_A \geq p_B &\Rightarrow \frac{\sqrt{p_A q_A}}{\sqrt{p_B q_B}} \geq 1 \quad \forall p_A, p_B \in (0, 1) \\ \Rightarrow p_A \geq p_B &\Rightarrow (n_A)_{\text{Neymann}} \geq (n_B)_{\text{Neymann}} \quad \forall p_A, p_B \in (0, 1) \end{aligned}$$

(which is obviously not desirable in terms of the ethical goal)

- \* Another goal, a compromise between the ethical goal and efficiency, is to minimize the expected number of failures for a fixed variance of  $\hat{p}_A - \hat{p}_B$ . The optimal allocation for this goal is :-

$$\frac{n_A}{n} = \frac{\sqrt{p_A}}{\sqrt{p_A} + \sqrt{p_B}}$$

- This allocation also has the advantage of allocating more patients to better treatment as :-

$$\sqrt{\frac{p_A}{p_B}} \geq 1 \implies (n_A)_{opt} \geq (n_B)_{opt}$$

so it serves both the goals simultaneously which is much desired.

- For more than 2 treatments i.e  $k$  treatments in general, it is still unclear how to find optimal allocations for general  $K$  treatment clinical trials !!

## 6 Target-Based Response-Adaptive Designs

- ❖ Because optimal allocation usually **depends on** some **unknown parameters**, we **cannot implement** it in practice, unless we **estimate** the **unknown parameters sequentially**.

- In this section, we introduce two allocation procedures that use **sequential estimation** of **unknown parameters**.
- We consider the case of comparing two treatments with binary responses.
- We also suppose that the **optimal allocation** is the **target proportion**.

### 6.1 Sequential Maximum Likelihood Procedure

- ❖ To start, allocate  $n_0 \geq 2$  patients to both treatments  $A$  and  $B$ .
- Assume that we have assigned  $j$  ( $j \geq 2n_0$ ) patients in the trial and their responses have been observed.
- Let  $\hat{p}_A$  and  $\hat{p}_B$  be the corresponding maximum likelihood estimators of  $p_A$  and  $p_B$  based on the  $j$  responses.
- Then we allocate the  $(j+1)^{th}$  patient to treatment  $A$  with probability :-

$$\frac{\sqrt{\hat{p}_A}}{\sqrt{\hat{p}_A} + \sqrt{\hat{p}_B}}$$

- ❖ From the invariance property of  $MLE$ , we can show that this allocation proportion, in a limiting sense, converges to the desired optimal allocation proportion  $\frac{\sqrt{p_A}}{\sqrt{p_A} + \sqrt{p_B}}$ .
- Using simulation we can give evidence that the limiting allocation proportion gets closer to the optimal allocation proportion  $\frac{\sqrt{p_A}}{\sqrt{p_A} + \sqrt{p_B}}$  for Trt A and  $\frac{\sqrt{p_B}}{\sqrt{p_A} + \sqrt{p_B}}$  for Trt B :-
- We plot the simulated allocation proportion for both Treatment A & B with  $p_A = 0.3, p_B = 0.7$  with increasing value of  $n$  :-
- So, theoretical the limiting proportions must be equal to  $\frac{\sqrt{0.3}}{\sqrt{0.3} + \sqrt{0.7}} \approx 0.396$  and  $\frac{\sqrt{0.7}}{\sqrt{0.3} + \sqrt{0.7}} \approx 0.604$  for Treatments A & B respectively.






Figure 3:  $n_A/n$  and  $n_B/n$  as a function of  $n$

## 6.2 Doubly Adaptive Biased Coin Design

✱ This procedure is a generalization of the sequential maximum likelihood procedure.

- At first, allocate  $n_0 \geq 2$  patients to both treatments  $A$  and  $B$ .
- Suppose that we have assigned  $j$  ( $j \geq 2n_0$ ) patients in the trial and their responses have been observed.
- Let  $\rho = \frac{\sqrt{p_A}}{\sqrt{p_A} + \sqrt{p_B}}$  be the desired allocation.

✱ Let  $\hat{\rho}$  be the desired allocation, replaced by current estimates  $\hat{p}_A$  and  $\hat{p}_B$ .

- Let  $j_A/j$  and  $j_B/j$  be the current proportions of patients that have already been allocated to  $A$  and  $B$ , respectively.
- Then we assign patient  $j + 1$  to treatment  $A$  with probability  $g(j_A/j, \hat{\rho})$ .
- Here  $g$  is an allocation function belonging to the family of functions :-

$$g(x, y) = \frac{y(y/x)^\gamma}{y(y/x)^\gamma + (1-y)(1-y/1-x)^\gamma} \text{ where } \gamma \geq 0$$

✱ Suppose the  $(j + 1)^{th}$  patient is allocated to Treatment  $A$ .

- Then we update the estimates  $\hat{p}_A, \hat{p}_B$  and then the optimal allocation estimate  $\hat{\rho}$  accordingly.
- Then we allocate the  $(j + 2)^{th}$  patient to Treatment  $A$  with probability  $g((j + 1)_A / (j + 1), \hat{\rho})$  where  $(j + 1)_A = j_A + 1$ .




Figure 4:  $p_A = 0.3, p_B = 0.7, \gamma = 0$

➡ Now, we simulate the Doubly Adaptive Biased Coin Design for different two pairs of  $(p_A = 0.3, p_B = 0.7)$  &  $(p_A = 0.6, p_B = 0.7)$  and also plot the allocation proportions for different values of  $\gamma$  parameter.

### 6.2.1 Role of Parameter $\gamma$ in Determining Variability of The Procedure

At the extreme, when  $\gamma = 0$ , we have the sequential maximum likelihood procedure, which has maximum variability :-

As  $\gamma$  increases, the procedure becomes more deterministic resulting in a reduction of variance using simulation this can be shown :-

For quite large values of  $\gamma (= 10)$ , the variability further decreases :-



Smaller the difference between  $p_A$  and  $p_B$ , larger is the variability of the procedure as we can notice it even doesn't seem to converge to the desired limits :-



So to stabilize the procedure, we require even larger values of  $\gamma$ , say  $\gamma = 20$  as we can see in the simulated plot :-

## 7 Important Issues in Adaptive Design

### 7.1 Variability and Power of Using Adaptive Designs

- \* When using response-adaptive designs in clinical trials, the number of patients assigned to each treatments ( $n_A$  &  $n_B$ ) are random variables.

Figure 5:  $p_A = 0.3, p_B = 0.7, \gamma = 5$ Figure 6:  $p_A = 0.3, p_B = 0.7, \gamma = 10$

Figure 7:  $p_A = 0.6, p_B = 0.7, \gamma = 0$ Figure 8:  $p_A = 0.6, p_B = 0.7, \gamma = 20$

- Therefore the power  $P(\text{rejecting } \mathcal{H}_0 | \mathcal{H}_0 \text{ false})$  (for most testing hypotheses and alternatives) is also a random variable. Here we generally consider hypothesis like :-

$$\begin{aligned}\mathcal{H}_0 : p_A &= p_B \\ \mathcal{H}_1 : p_A &\neq p_B\end{aligned}$$

- The variability of allocation has a strong effect on the power.
- Hu and Rosenberger show that the **average power of a randomization procedure** is a **decreasing function** of the **variability of the procedure**.
- ❖ The drop-the-loser rule has minimum variability (lower bound) in the class of all response-adaptive procedures targeting urn allocation  $\frac{q_B}{q_A + q_B}$ .
  - The doubly adaptive biased coin design can directly target any given allocation (may depend on unknown parameters).
  - At the extreme, when  $\gamma = 0$ , we have the sequential maximum likelihood procedure, which has the highest variability.
- ❖ As  $\gamma$  tends to  $\infty$ , we have a procedure that attains the lower bound of any randomization procedure targeting the same allocation.
  - As  $\gamma$  becomes smaller, we have more randomization, but also more variability.
  - Overall, the doubly adaptive biased coin procedure is the most favorable design as :-
    - It is flexible in terms of targeting any desired allocation.
    - It can be applied to different types of responses.
    - One can tune the parameter  $\gamma$  to reflect the **tradeoff** between the **power** and **variability**, and the tradeoff between **degree of randomization** and **expected treatment successes**.

## 7.2 Sample Size of Adaptive Designs

- ❖ It is usually difficult to determine the required sample size for response-adaptive designs.
  - This is because the allocation probabilities keep changing during a clinical trial when using response-adaptive design.
  - For a fixed sample size, the number of patients assigned to each treatment is a random variable.
  - Therefore the power is also a random variable for a fixed sample size.
  - In the literature, sample sizes of response-adaptive designs are calculated by ignoring the randomness of the allocations.

## 8 Applying Adaptive Designs

- ❖ The randomized play-the-winner rule was used in the highly controversial extracorporeal membrane oxygenation (ECMO) study.

- Adaptive designs have been implemented in several clinical trials such as :-
  - A trial of crystalloid preload in hypotension for cesarean patients.
  - A trial of fluoxetine vs. placebo in depression patients.
  - A four-arm trial in depression.
- Adaptive designs have also been used extensively in adaptive learning algorithms, game theory, as well as dynamical systems.

## 9 Some Important Issues Regarding Adaptive Designs

- \* In the above discussion, we assume that individual patient outcome will be immediately available.
  - For clinical trials with delayed responses, we can update the urn when the response becomes available.
  - For doubly adaptive biased coin designs, the unknown parameters are estimated sequentially and the delayed responses effect these estimators.
  - The properties of doubly adaptive biased coin design with delayed responses are unknown, and this is a topic of future research.